Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRallybio Corp

Rallybio Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
15.56 USD -0.19 ( 1.21%)
Last update at 2026-11-09T15:17:00Z
VOLUME
15195
Market Cap
66.32M

Momentum Score

…

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
15.53
Low
16.00
High
52 Week Price Range
1.23
Low
9.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Rallybio Corp is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and serious genetic conditions. Long-term growth may be driven by pipeline clinical-trial progress, potential regulatory approvals or orphan-designation pathways, and partnerships or licensing that could expand development resources, which may appeal to investors seeking exposure to rare-disease therapeutics.
Key investment risks include high clinical and regulatory uncertainty, likely ongoing cash burn with recurrent financing needs, and limited commercial revenue until any candidate achieves approval.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
15.75
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-62.43%
Net Debt
-24.10M
ROCE
-63.83%
Diluted EPS TTM
-1.88

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -65.58M -45.51M -24.94M -17.46M
Net income -66.49M -47.01M -24.93M -17.63M
Selling general administrative 27.20M 18.74M 7.67M 6.28M
Reconciled depreciation 0.17M 0.11M 0.06M 0.03M
Ebit -67.88M -45.65M -25.30M -17.64M
Ebitda -65.58M -45.50M -24.83M -17.39M
Depreciation and amortization 2.31M 0.15M 0.47M 0.25M
Non operating income net other 1.02M -1.35M - -
Operating income -67.88M -45.65M -25.30M -17.64M
Other operating expenses 67.88M 45.65M 25.30M 17.64M
Interest expense 2.31M 0.01M 0.05M 0.04M
Tax provision - 0.00M -0.01M 0.00M
Interest income 1.96M 0.05M 0.17M 0.20M
Net interest income 1.96M 0.04M 0.12M 0.16M
Income tax expense 0.91M 1.50M -0.01M 0.17M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 67.88M 45.65M 25.30M 17.64M
Total other income expense net 2.31M 0.14M 0.36M 0.18M
Net income from continuing ops -65.58M -45.51M -26.45M -17.56M
Net income applicable to common shares -66.65M -45.51M -26.45M -17.56M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 115.62M 180.44M 182.19M 141.86M 21.61M
Other current assets 4.86M 1.05M 5.54M 1.03M 1.46M
Total liab 9.44M 11.12M 6.58M 187.88M 41.89M
Total stockholder equity 106.18M 169.32M 175.60M -47.01M -20.57M
Other current liab 8.07M 9.45M 5.95M 4.26M 2.95M
Common stock 0.00M 0.00M 0.00M 0.45M 0.23M
Capital stock 0.00M 0.00M 0.00M - -
Retained earnings -235.25M -160.68M -94.03M -47.01M -20.57M
Other liab - - 0.03M 0.01M 0.94M
Other assets - - 182.19M - -
Cash 24.49M 56.96M 175.33M 140.23M 19.46M
Total current liabilities 9.26M 10.74M 6.55M 5.84M 3.81M
Net debt -24.10M -56.40M -175.33M -140.23M -19.46M
Short term debt 0.22M 0.18M - - -
Short long term debt total 0.39M 0.56M - - -
Other stockholder equity 341.41M 330.21M 269.63M 47.01M 20.57M
Property plant equipment - 0.39M 0.51M 0.29M 0.20M
Total current assets 114.79M 179.50M 180.87M 141.26M 20.92M
Long term investments 0.24M 0.03M 0.81M 0.31M 0.49M
Net tangible assets - 169.32M 175.60M -46.02M -20.28M
Short term investments 85.44M 112.04M - - -
Accounts payable 0.98M 1.11M 0.60M 1.58M 0.86M
Accumulated other comprehensive income 0.01M -0.21M - - -
Common stock total equity - 0.00M 0.00M - -
Retained earnings total equity - -160.68M -94.03M - -
Non currrent assets other 0.24M 0.03M 0.81M - -
Non current assets total 0.83M 0.94M 1.32M 0.60M 0.69M
Capital lease obligations 0.39M 0.56M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -112.12M -2.00M -1.94M -1.94M
Change to liabilities 3.71M 0.73M 0.72M 0.73M
Total cashflows from investing activities -112.17M -2.33M -2.07M -0.19M
Total cash from financing activities 51.08M 82.97M 144.89M 31.57M
Change to operating activities -1.42M -2.80M 1.40M 1.34M
Net income -66.65M -47.01M -26.45M -17.56M
Change in cash -118.38M 35.10M 120.78M 16.35M
Begin period cash flow 175.33M 140.23M 19.46M 3.10M
End period cash flow 56.96M 175.33M 140.23M 19.46M
Total cash from operating activities -57.28M -45.53M -22.04M -15.03M
Issuance of capital stock 51.53M 86.20M 145.21M 31.60M
Depreciation 0.17M 0.11M 0.06M 0.03M
Sale purchase of stock 0.22M 82.97M - -
Other cashflows from financing activities -0.67M -3.23M -0.32M -0.03M
Change to netincome 10.57M 3.65M 2.23M 0.44M
Capital expenditures 0.05M 0.33M 0.14M 0.19M
Cash flows other operating -4.64M -3.00M - -
Cash and cash equivalents changes -118.38M 35.10M - -
Change in working capital -0.94M -3.78M 2.12M 2.07M
Stock based compensation 9.50M 3.65M 0.70M 0.19M
Other non cash items 0.64M 1.50M 1.52M 0.14M
Free cash flow -57.34M -45.87M -22.18M -15.21M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RLYB
Rallybio Corp		 -0.19
1.21%		 15.56 - - - 0.83 -1.41
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Rallybio Corp

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

234 Church Street, New Haven, CT, United States, 06510

203 859 3820

https://www.rallybio.com

30

Name Title Year Born
Dr. Martin W. MacKay Ph.D. Co-Founder, CEO & Chairman 1956
Dr. Stephen Uden M.B, M.D. Co- Founder, Pres, COO & Chief Scientific Officer 1958
Mr. Jeffrey M. Fryer CPA Co-Founder, CFO & Treasurer 1970
Ms. Ami Bavishi Head of Investor Relations & Corp. Communications NA
Dr. Steven W. Ryder F.A.C.P, M.D. Chief Medical Officer 1951
Dr. Martin W. MacKay Ph.D. Co-Founder & Executive Chairman 1956
Dr. Stephen Uden M.B, M.D. Co-Founder, President, CEO & Director 1958
Mr. Jonathan I. Lieber M.B.A. CFO & Treasurer 1970
Ms. Ami Bavishi Head of Investor Relations & Corporate Communications NA
Dr. Steven W. Ryder F.A.C.P, M.D. Chief Medical Officer 1952

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…